Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
Alliance Foundation Trials, LLC.
Erica L Mayer; Christian Fesl; Dominik Hlauschek; Laura Garcia-Estevez; Harold J Burstein; Nicholas Zdenkowski; Viktor Wette; Kathy D Miller; Marija Balic; Ingrid A Mayer; David Cameron; Eric P Winer; José Juan Ponce Lorenzo; Diana Lake; Gunda Pristauz-Telsnigg; Tufia C Haddad; Lois Shepherd; Hiroji Iwata; Matthew Goetz; Fatima Cardoso; Tiffany A Traina; Dhanusha Sabanathan; Urs Breitenstein; Kerstin Ackerl; Otto Metzger Filho; Karin Zehetner; Kadine Solomon; Sarra El-Abed; Kathy Puyana Theall; Dongrui Ray Lu; Amylou Dueck; Michael Gnant; Angela DeMichele
Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ.